A Semi-mechanistic Model for the Effects of a Novel Glucagon Receptor Antagonist on Glucagon and the Interaction Between Glucose, Glucagon, and Insulin Applied to Adaptive Phase II Design
Journal Title: The AAPS Journal - Year 2014, Vol 16, Issue 6
Abstract
A potent novel compound (MK-3577) was developed for the treatment of type 2 diabetes mellitus (T2DM) through blocking the glucagon receptor. A semi-mechanistic model was developed to describe the drug effect on glucagon and the interaction between glucagon, insulin, and glucose in healthy subjects (N = 36) during a glucagon challenge study in which glucagon, octreotide (Sandostatin), and basal insulin were infused for 2 h starting from 3, 12, or 24 h postdose of a single 0–900 mg MK-3577 administration. The drug effect was modeled by using an inhibitory Emax model (Imax = 0.96 and IC50 = 13.9 nM) to reduce the ability of glucagon to increase the glucose production rate (GPROD). In addition, an Emax model (Emax = 0.79 and EC50 = 575 nM) to increase glucagon secretion by the drug was used to account for the increased glucagon concentrations prechallenge (via compensatory feedback). The model adequately captured the observed profiles of glucagon, glucose, and insulin pre- and postchallenge. The model was then adapted for the T2DM patient population. A linear model to correlate fasting plasma glucose (FPG) to weighted mean glucose (WMG) was developed and provided robust predictions to assist with the dose adjustment for the interim analysis of a phase IIa study.
Authors and Affiliations
Joanna Z. Peng, William S. Denney, Bret J. Musser, Rong Liu, Kuenhi Tsai, Lanyan Fang, Marc L. Reitman, Matthew D. Troyer, Samuel S. Engel, Lei Xu, Aubrey Stoch, Julie A. Stone, Ken G. Kowalski
Keywords
Related Articles
- EP ID EP681733
- DOI 10.1208/s12248-014-9648-x
- Views 84
- Downloads 0
Therapeutic Paint of Cidofovir/Sucralfate Gel Combination Topically Administered by Spraying for Treatment of orf virus Infections
The aim of the research was to study a new cidofovir/sucralfate drug product to be used as a spray for treating the mucosal and/or skin lesions. The product, i.e., a water suspension of sucralfate (15% w/w) and cidofovir...
Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics
Monoclonal antibodies are increasingly being developed to treat multiple disease areas, including those related to oncology, immunology, neurology, and ophthalmology. There are multiple factors, such as charge, size, neo...
The chinchilla microdialysis model for the study of antibiotic distribution to middle ear fluid
In cases of slow or limited penetration of an antibiotic to the site of infection such as in acute otitis media (the middle ear), plasma levels of the agent may not reflect the concentrations that are relevant in determi...
Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates
k Opioids as potential treatments for stimulant dependence
Stimulant abuse is a major problem in the United States and the development of pharmacological treatments for stimulant abuse remains an important therapeutic goal. Classically, the “dopamine hypothesis”...